The 2016 updated EULAR evidence-based recommendations for the management of gout aim to provide physicians and patients with the best strategies to manage hyperuricaemia and flare-ups. The recommendations are based on a systematic review of the literature and a Delphi consensus approach. Key changes from the 2006 guidelines include early initiation and titration of urate-lowering therapy (ULT), the recommendation to combine xanthine oxidase inhibitors (XOIs) with uricosurics, and the suggestion to target serum uric acid (SUA) levels at <5 mg/dL (300 μmol/L) for severe gout. Colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), oral or intra-articular steroids, and interleukin-1 (IL-1) blockers are recommended for treating flares. Allopurinol is the first-line ULT, with febuxostat and pegloticase as alternatives. The recommendations emphasize the importance of patient education, lifestyle modifications, and lifelong management of gout.The 2016 updated EULAR evidence-based recommendations for the management of gout aim to provide physicians and patients with the best strategies to manage hyperuricaemia and flare-ups. The recommendations are based on a systematic review of the literature and a Delphi consensus approach. Key changes from the 2006 guidelines include early initiation and titration of urate-lowering therapy (ULT), the recommendation to combine xanthine oxidase inhibitors (XOIs) with uricosurics, and the suggestion to target serum uric acid (SUA) levels at <5 mg/dL (300 μmol/L) for severe gout. Colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), oral or intra-articular steroids, and interleukin-1 (IL-1) blockers are recommended for treating flares. Allopurinol is the first-line ULT, with febuxostat and pegloticase as alternatives. The recommendations emphasize the importance of patient education, lifestyle modifications, and lifelong management of gout.